FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226269919> ?p ?o ?g. }

• W4226269919 endingPage "1230" @default.
• W4226269919 startingPage "1220" @default.
• W4226269919 abstract "The benefit of neoadjuvant chemoradiotherapy in resectable and borderline resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial failed to demonstrate a statistically significant overall survival (OS) benefit. The long-term results are reported.In this multicenter, phase III trial, patients with resectable and borderline resectable pancreatic cancer were randomly assigned (1:1) to neoadjuvant chemoradiotherapy or upfront surgery in 16 Dutch centers. Neoadjuvant chemoradiotherapy consisted of three cycles of gemcitabine combined with 36 Gy radiotherapy in 15 fractions during the second cycle. After restaging, patients underwent surgery followed by four cycles of adjuvant gemcitabine. Patients in the upfront surgery group underwent surgery followed by six cycles of adjuvant gemcitabine. The primary outcome was OS by intention-to-treat. No safety data were collected beyond the initial report of the trial.Between April 24, 2013, and July 25, 2017, 246 eligible patients were randomly assigned to neoadjuvant chemoradiotherapy (n = 119) and upfront surgery (n = 127). At a median follow-up of 59 months, the OS was better in the neoadjuvant chemoradiotherapy group than in the upfront surgery group (hazard ratio, 0.73; 95% CI, 0.56 to 0.96; P = .025). Although the difference in median survival was only 1.4 months (15.7 months v 14.3 months), the 5-year OS rate was 20.5% (95% CI, 14.2 to 29.8) with neoadjuvant chemoradiotherapy and 6.5% (95% CI, 3.1 to 13.7) with upfront surgery. The effect of neoadjuvant chemoradiotherapy was consistent across the prespecified subgroups, including resectable and borderline resectable pancreatic cancer.Neoadjuvant gemcitabine-based chemoradiotherapy followed by surgery and adjuvant gemcitabine improves OS compared with upfront surgery and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer." @default.
• W4226269919 created "2022-05-05" @default.
• W4226269919 creator A5002147373 @default.
• W4226269919 creator A5002633658 @default.
• W4226269919 creator A5003973735 @default.
• W4226269919 creator A5006641161 @default.
• W4226269919 creator A5012438017 @default.
• W4226269919 creator A5015416945 @default.
• W4226269919 creator A5017560439 @default.
• W4226269919 creator A5018004001 @default.
• W4226269919 creator A5020655761 @default.
• W4226269919 creator A5023698533 @default.
• W4226269919 creator A5024976681 @default.
• W4226269919 creator A5031137165 @default.
• W4226269919 creator A5033788401 @default.
• W4226269919 creator A5039275887 @default.
• W4226269919 creator A5041935065 @default.
• W4226269919 creator A5043134557 @default.
• W4226269919 creator A5043942519 @default.
• W4226269919 creator A5049787068 @default.
• W4226269919 creator A5051056050 @default.
• W4226269919 creator A5052876669 @default.
• W4226269919 creator A5054231020 @default.
• W4226269919 creator A5058791475 @default.
• W4226269919 creator A5063019493 @default.
• W4226269919 creator A5065098749 @default.
• W4226269919 creator A5068302495 @default.
• W4226269919 creator A5072405531 @default.
• W4226269919 creator A5074911126 @default.
• W4226269919 creator A5074957985 @default.
• W4226269919 creator A5078260564 @default.
• W4226269919 creator A5086772172 @default.
• W4226269919 creator A5087659165 @default.
• W4226269919 creator A5089069968 @default.
• W4226269919 date "2022-04-10" @default.
• W4226269919 modified "2023-10-14" @default.
• W4226269919 title "Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial" @default.
• W4226269919 cites W1968812902 @default.
• W4226269919 cites W1994177577 @default.
• W4226269919 cites W2013507617 @default.
• W4226269919 cites W2017955572 @default.
• W4226269919 cites W2107539963 @default.
• W4226269919 cites W2129197203 @default.
• W4226269919 cites W2138582833 @default.
• W4226269919 cites W2294867706 @default.
• W4226269919 cites W2526895401 @default.
• W4226269919 cites W2581973599 @default.
• W4226269919 cites W2626891310 @default.
• W4226269919 cites W2748935831 @default.
• W4226269919 cites W2796434454 @default.
• W4226269919 cites W2799575632 @default.
• W4226269919 cites W2883551349 @default.
• W4226269919 cites W2885738414 @default.
• W4226269919 cites W2903623792 @default.
• W4226269919 cites W2912196744 @default.
• W4226269919 cites W2928808042 @default.
• W4226269919 cites W2999417355 @default.
• W4226269919 cites W3008190574 @default.
• W4226269919 cites W3017314211 @default.
• W4226269919 cites W3031901305 @default.
• W4226269919 cites W3137285239 @default.
• W4226269919 cites W3138807170 @default.
• W4226269919 cites W4211253487 @default.
• W4226269919 cites W4247012710 @default.
• W4226269919 cites W592682419 @default.
• W4226269919 cites W993424279 @default.
• W4226269919 doi "https://doi.org/10.1200/jco.21.02233" @default.
• W4226269919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35084987" @default.
• W4226269919 hasPublicationYear "2022" @default.
• W4226269919 type Work @default.
• W4226269919 citedByCount "191" @default.
• W4226269919 countsByYear W42262699192022 @default.
• W4226269919 countsByYear W42262699192023 @default.
• W4226269919 crossrefType "journal-article" @default.
• W4226269919 hasAuthorship W4226269919A5002147373 @default.
• W4226269919 hasAuthorship W4226269919A5002633658 @default.
• W4226269919 hasAuthorship W4226269919A5003973735 @default.
• W4226269919 hasAuthorship W4226269919A5006641161 @default.
• W4226269919 hasAuthorship W4226269919A5012438017 @default.
• W4226269919 hasAuthorship W4226269919A5015416945 @default.
• W4226269919 hasAuthorship W4226269919A5017560439 @default.
• W4226269919 hasAuthorship W4226269919A5018004001 @default.
• W4226269919 hasAuthorship W4226269919A5020655761 @default.
• W4226269919 hasAuthorship W4226269919A5023698533 @default.
• W4226269919 hasAuthorship W4226269919A5024976681 @default.
• W4226269919 hasAuthorship W4226269919A5031137165 @default.
• W4226269919 hasAuthorship W4226269919A5033788401 @default.
• W4226269919 hasAuthorship W4226269919A5039275887 @default.
• W4226269919 hasAuthorship W4226269919A5041935065 @default.
• W4226269919 hasAuthorship W4226269919A5043134557 @default.
• W4226269919 hasAuthorship W4226269919A5043942519 @default.
• W4226269919 hasAuthorship W4226269919A5049787068 @default.
• W4226269919 hasAuthorship W4226269919A5051056050 @default.
• W4226269919 hasAuthorship W4226269919A5052876669 @default.
• W4226269919 hasAuthorship W4226269919A5054231020 @default.
• W4226269919 hasAuthorship W4226269919A5058791475 @default.
• W4226269919 hasAuthorship W4226269919A5063019493 @default.
• W4226269919 hasAuthorship W4226269919A5065098749 @default.

• next